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Abstract
Background-Patients with familial ad-
enomatous polyposis are not only at high
risk of developing adenomas in the
colorectum but a substantial number of
patients also develop polyps in the duo-
denum. Because treament of duodenal
polyps is extremely difficult and it is
unknown how many patients ultimately
develop duodenal cancer, the value of
surveillance of the upper digestive tract is
uncertain.
Aims-(l) To assess the cumulative risk of
duodenal cancer in a large series of poly-
posis patients. (2) To develop a decision
model to establish whether surveillance
would lead to increased life expectancy.
Methods-Risk analysis was performed
in 155 Dutch polyposis families including
601 polyposis patients, and 142 Danish
families including 376 patients. Obser-
vation time was from birth until date of
last contact, death, diagnosis of duodenal
cancer, or closing date ofthe study.
Results-Seven Dutch and five Danish
patients developed duodenal cancer. The
lifetime risk of developing this cancer by
the age of 70 was 40/0 (95%/o confidence
interval 1-7%) in the Dutch series and 30/o
(95% confidence interval 0 60/o) in the
Danish series. Decision analysis showed
that surveillance led to an increase in life
expectancy by seven months.
Conclusions-Surveillance of the upper
digestive tract led to a moderate gain in
life expectancy. Future studies should
evaluate whether this increase in life
expectancy outweighs the morbidity of
endoscopic examination and proximal
pancreaticoduodenectomy.
(Gut 1997; 40: 716-719)
Keywords: familial adenomatous polyposis, duodenal
cancer, surveillance, decision analysis,
pancreaticoduodenectomy.
Familial adenomatous polyposis (FAP) or
Bussey-Gardner polyposis is an autosomal
dominant disease due to a mutated aden-
omatous polyposis coli (APC) gene and is
characterised by the development of hundreds
of adenomas in the colon.1`3 Since the disease
was first recognised, there have been numerous
reports of other lesions outside the colon.
The spectrum of lesions reported in FAP
includes multiple osteomas of the cranium and
mandibles, multiple epidermoid cysts of the
skin, dental abnormalities, desmoid tumours of
the abdominal wall and abdomen, bilateral
patches of congenital hypertrophy of the
retina pigment epithelium, and fundic gland
polyposis.4 I
During the 1970s, an increasing number of
case reports of FAP patients with malignancy
of the periampullary region and proximal duo-
denum appeared.6 ' These reports focused
attention on the upper gastrointestinal (GI)
tract and led to series of reports on gastroduo-
denoscopy of groups of polyposis patients.
Most recorded that at least two thirds of the
polyposis patients also had duodenal aden-
omas.8-l' The first question to arise at that time
was: do the adenomas of the duodenum follow
the adenoma-carcinoma sequence observed in
the colorectum? At present, there is ample
evidence suggesting that this is the case.
Duodenal or periampullary adenocarcinoma
has been found to occur in patients with FAP
at a much higher frequency compared with the
general population16 17 and 40% of patients
with duodenal cancer have synchronous duo-
denal adenomas.'8
Despite this information it is still unknown
how many patients with duodenal polyps
ultimately develop duodenal cancer. As such
information should be available before the
introduction of a large scale surveillance pro-
gramme for patients with polyposis, we evalu-
ated the lifetime risk of duodenal cancer in a
large series of patients with polyposis from the
Polyposis Registries in The Netherlands and
Denmark. In addition, a decision analysis
model was developed for prediction ofwhether
surveillance of the upper GI tract would lead
to an increased life expectancy.
Methods
THE DUTCH AND DANISH POLYPOSIS REGISTRIES
Families suspected of FAP are referred to the
registries from all parts of both countries.19
Personal data, results of investigation, patho-
logy reports, and results of treatment are
collected for the registries. The criteria used for
the diagnosis of an FAP family were that there
should be at least one relative with more than
100 colorectal adenomas, or that linkage or
mutation analysis had proven that the APC
gene was responsible for the disease in the
family.
RISK ANALYSIS
For risk assessment, patients with polyposis
were studied with respect to risk of the
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Decision treefor a 30year old man with familial adenomatous polyposis.
development of duodenal cancer from birth
until death. The data were analysed by life
table analysis methods. Observation time was
until date of last contact, death, date of
diagnosis of a duodenal cancer, or closing date
of the study, 31 December 1995.
DECISION ANALYSIS
We applied the technique of decision analysis
to a hypothetical male polyposis patient, 30
years of age, who had undergone colectomy
and ileorectal anastomosis. The first step was
to identify all the alternative actions, treat-
ments, and outcomes that could occur for the
patient in question. On the basis of this, a
decision model (shown in the Figure) that
displays these elements in their proper time
sequence was developed. Points where the tree
branches ("nodes") are square ("choice
nodes") when they imply a decision under the
control of the physician, and round ("chance
nodes") if a chance outcome occurs.
Results
RISK ANALYSIS
On 31 December 1995, the Dutch Popyposis
Register included about 200 families with FAP.
Data collection was completed in the first 155
families and these families were selected for the
present study. The 155 families included 711
patients with FAP. The diagnosis of FAP was
confirmed by pathology and/or medical reports
in 601 patients. One hundred and eighteen
patients died; the cause of death is known in
910% of the patients. Among the 601 patients,
seven developed duodenal cancer (including
one suspected case). The mean age at diag-
nosis of duodenal cancer was 47 years (range
39-53). The cumulative risk of developing
duodenal cancer by age 70 was 4% (95%
confidence interval l-7%). The number of
patients at risk by age 70 was 27.
On 31 December 1995, the Danish Poly-
posis Register included 142 FAP families with
a completed data collection, including 454
patients of whom 376 had a histologically
verified FAP. The cause of death is known
for all 160 deceased patients. In five patients
data were insufficient. Of the remaining 371
affected patients, five developed duodenal
cancer; the mean age at diagnosis was 51 years
(range 43-77). The cumulative risk of devel-
oping duodenal cancer by age 70 was 3% (95%
confidence interval O-6%). The number of
patients at risk by age 70 was nine.
DECISION ANALYSIS
The decision tree for the 30 year old polyposis
patient with corresponding probabilities is
shown in the Figure. We assumed that the life
expectancy of a 30 year old polyposis patient
would be shortened due to desmoid disease,
the mortality due to secondary rectal surgery,
and the mortality due to rectal cancer. There-
fore, we estimated that the average life expec-
tancy of this 30 year old patient would be 40
years instead of 45 years. For staging of
duodenal polyposis in most studies use was
made of the so-called Spigelman classifi-
cation.'4 This staging system is based on a set
of arbritary scores using postulated adenoma/
cancer risk factors. These are the architecture
("villousness"), the degree of dysplasia, and
the size and number of the duodenal polyps.
Stage I represents minor disease and stage IV
indicates major or advanced duodenal poly-
posis (Table I). When stage IV duodenal
polyposis is found, surgical intervention may
be considered. The probability of finding
Spigelman stage IV is based on findings of two
prospective studies on the natural history of
duodenal adenomatosis.
22
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TABLE I Classification ofduodenal adenomas according to
Spigelman'4
Points
Polyps 1 2 3
Number <4 5-20 >20
Size (mm) 0-4 5-10 >10
Histology Tubular Tubulo-villous Villous
Dysplasia Mild Moderate Severe
Spigelman stage I: 1-4; stage II: 5-6; stage III: 7-8; stage IV:
9-12 points.
One analysis was conducted at the St Mark's
Polyposis Registry in London'4 and the other
in five European countries.'5 The British study
showed that 11 (1 1%) out of 102 FAP patients
had stage IV duodenal polyposis. In the
European multicentre study, 27 patients out of
310 (9%) had stage IV duodenal polyposis.
In the multicentre study, 7% of the patients
aged between 20 and 40 years, and 11% of
those aged between 40 and 60 years had
stage IV duodenal adenomatosis (personal
communication, S Bulow). The cumulative
risk of developing stage IV adenomatosis is
therefore at least 110%. The mean age of the
patients identified with Spigelman stage IV was
51 years in the British study and 38 years in
the multicentre study. On these grounds we
estimated that the average age of patients who
reached stage IV duodenal polyposis would be
45 years. If a pancreaticoduodenotomy is
performed and the patient dies as a result
of complications of this procedure, the aver-
age life expectancy of a 30 year old patient
would amount to 15 years. The periopera-
tive mortality ofpancreaticoduodenectomy has
declined during the past decade and is now
about 5%.
The cumulative risk of duodenal cancer by
age 70 in the present series is 3-4%. The mean
age at diagnosis of duodenal cancer in this
study and in three others was about 50 years.
The life expectancy of a patient who develops
duodenal cancer is estimated at two years.
Hence, the life expectancy of the hypothetical
30 year old patient is on average 22 years if he
develops duodenal cancer.
We then worked our way back through the
decision tree by "folding it back" from right to
left. By multiplying the life expectancy by the
probabilities of occurrence of each option, and
summing them for each branch, we could
TABLE ii The impact ofvarious probabilities ofdeveloping
duodenal cancer, stage IVduodenal adenomatosis, and
perioperative mortality on life expectancy
Life expectancy (y)
SurveiUlance No surveillance
Probability ofduodenal cancer (%/o)
4 39.9 39.3
10 399 38-2
15 39 9 37-3
Probability ofstage IV duodenal adenomatosis (%)
1 1 39-9 39-3
15 39-8 39-3
20 39 7 39-3
Probability ofperioperative mortality (%/6)
2 399 393
4 39.9 39.3
6 39-8 39-3
assign life expectancies to the various nodes.
The calculations showed that the option of
surveillance led to an increase in life expec-
tancy by seven months. The key variables -
the cumulative risk of stage IV duodenal
adenomatosis, duodenal cancer, and the risk of
mortality due to pancreaticoduodenotomy -
were varied over a plausible range to assess
their impact on the outcome of the model
(Table II). The probability of developing
duodenal cancer appeared to be the most
important variable.
Discussion
After the realisation that a majority of patients
with polyposis develop adenomas in the duo-
denum, many investigators recommended
surveillance of the upper GI tract. However,
before establishing such a surveillance pro-
gramme, a more critical evaluation of the pros
and cons of surveillance should be performed.
In particular, the difficulties for effective
treatment posed by duodenal adenomas make
the benefit of surveillance of the upper GI tract
questionable.
In the assessment of population screening,
the criteria formulated by Wilson and Jungner20
are usually applied. These criteria are also
appropriate in the assessment of surveillance
of high risk groups such as patients with
polyposis. According to these criteria, the natu-
ral history of duodenal adenomas should be
known, a curative treatment should be avail-
able, and there should be evidence that early
treatment leads to an improved prognosis.
With respect to the natural history of
duodenal adenomas, the most urgent question
is "do the duodenal polyps have the same
malignant potential as the colonic polyps?"
Earlier studies'7 indicated that the relative risk
of duodenal cancer in FAP was very high, but
such information is less useful in the decision
making process, because the incidence of
duodenal cancer in the general population is
extremely low. Much more important would
be to know the lifetime risk of developing
duodenal cancer. The present study revealed
that the cumulative risk of duodenal cancer
was less than 5% by the age of 70. Although
prospective studies are needed to confirm our
findings, such studies have the disadvantage
that the screening examinations will inevitably
lead to early detection of premalignant disease
and to early surgical intervention, which will
interfere with the assessment of the duodenal
cancer risk.
The treatment of duodenal adenomas in our
patients is limited by a number of factors.
Endoscopic snaring may be made impossible
by the presence of large numbers of polyps or
by the usual sessile nature of the polyps.
Endoscopic electrocoagulation, if repeated
very often, will lead to considerable scarring,
which in the periampullary area might cause
strictures. Laser ablation of polyps via the
endoscope can be used, but carries the risk of
duodenal perforation. Polyp removal by (sur-
gical) duodenotomy consisting of submucosal
infiltration and local excision of all polyps is
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not recommended, because a recent study has
shown recurrence in all patients treated by this
technique within a short time.2" To summarise,
the only curative treatment appears to be a
proximal pancreaticoduodenotomy. Such an
operation has considerable potential morbidity
and mortality which makes the indication for
and the timing of surgery extremely difficult.
Criteria of size, rapid growth, polyp induration,
or consistently severe dysplasia or villous
change suggest that intervention is necessary.
In the above mentioned British study, among
the 10 patients with stage IV adenomatosis at
the first endoscopy, one developed duodenal
cancer and two other patients are suspected of
having this type of cancer.22 Thus surgery may
be considered in patients that consistently have
stage IV duodenal adenomatosis.
Evidence that early treatment leads to
improvement of the prognosis is not yet
available, and it will probably take a long time
to collect such information. The best way to
demonstrate the benefits of surveillance would
be by randomised controlled studies showing
a higher survival rate. Such studies will, how-
ever, be difficult to carry out in view of the
extremely high risk of premalignant duodenal
disease. Therefore, we decided to apply de-
cision analysis to predict whether surveillance
might lead to an increase in life expectancy.
The calculations showed that surveillance
increased the life expectancy by seven months
if surgery was performed after detection of
stage IV adenomatosis. Sensitivity analysis
showed that the probability of duodenal cancer
had the strongest effect on the outcome com-
pared with the probability of developing duo-
denal adenomatosis stage IV or perioperative
mortality.
To summarise, the present analysis revealed
that surveillance may lead to a moderate gain
in life expectancy. Therefore, before starting
surveillance of the upper digestive tract, it is
important to explain to the patients that the
risk of developing duodenal cancer is relatively
low and that the only curative treatment for
severe duodenal adenomatosis is a major
operation with substantial morbidity and
mortality (in addition to the morbidity from
duodenoscopy). On the basis of this infor-
mation the patients may be able to decide
whether the potential gain in life expectancy
outweighs the adverse effects of surveillance
and treatment. If the patient prefers to be
under surveillance, the screening protocol
should start by the age of 30 years. Starting at
an earlier age can be considered to offer no
clinical benefit, as reports of duodenal cancer
before this age are extremely rare. The recom-
mended interval between examinations is one
to three years depending on the findings.
Ideally, the results should be collected in a
uniform manner at a regional or national
registry which will permit future evaluation.
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